These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21864624)

  • 41. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
    Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H
    J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.
    Cox RJ; Major D; Pedersen G; Pathirana RD; Hoschler K; Guilfoyle K; Roseby S; Bredholt G; Assmus J; Breakwell L; Campitelli L; Sjursen H
    PLoS One; 2015; 10(7):e0131652. PubMed ID: 26147369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
    Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
    BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.
    Svindland SC; Pedersen GK; Pathirana RD; Bredholt G; Nøstbakken JK; Jul-Larsen Å; Guzmán CA; Montomoli E; Lapini G; Piccirella S; Jabbal-Gill I; Hinchcliffe M; Cox RJ
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1181-93. PubMed ID: 23170900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
    Thongcharoen P; Auewarakul P; Hutagalung Y; Ong G; Gillard P; Drame M; Bock HL
    J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.
    Cox F; Saeland E; Baart M; Koldijk M; Tolboom J; Dekking L; Koudstaal W; Lövgren Bengtsson K; Goudsmit J; Radošević K
    Virol J; 2015 Dec; 12():210. PubMed ID: 26643820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.
    Cox RJ; Madhun AS; Hauge S; Sjursen H; Major D; Kuhne M; Höschler K; Saville M; Vogel FR; Barclay W; Donatelli I; Zambon M; Wood J; Haaheim LR
    Vaccine; 2009 Mar; 27(13):1889-97. PubMed ID: 19368768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
    Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
    Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
    Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
    Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus.
    Hwang SD; Kim HS; Cho SW; Seo SH
    Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
    Baras B; Stittelaar KJ; Kuiken T; Jacob V; Bernhard R; Giannini S; de Waal L; van Amerongen G; Simon JH; Osterhaus AD; Hanon E; Mossman SP
    Vaccine; 2011 Mar; 29(11):2092-9. PubMed ID: 21237275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.
    Bresson JL; Perronne C; Launay O; Gerdil C; Saville M; Wood J; Höschler K; Zambon MC
    Lancet; 2006 May; 367(9523):1657-64. PubMed ID: 16714186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.
    Svindland SC; Jul-Larsen Å; Pathirana R; Andersen S; Madhun A; Montomoli E; Jabbal-Gill I; Cox RJ
    Influenza Other Respir Viruses; 2012 Mar; 6(2):90-100. PubMed ID: 21749672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.